Related references
Note: Only part of the references are listed.Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
F. Gomez-Garcia et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
Zarif K. Jabbar-Lopez et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
D. M. Saunte et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials
Iain J. Marshall et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2016)
Effectiveness of Biologic and Conventional Systemic Therapies in Adults with Chronic Plaque Psoriasis in Daily Practice: A Systematic Review
Jeffrey Zweegers et al.
ACTA DERMATO-VENEREOLOGICA (2016)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2016)
Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks
Yuan Yu Michael Huang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
K. B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
PASI90 response: the new standard in therapeutic efficacy for psoriasis
L. Puig
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
J. Schmitt et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points
L. Puig et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Rosa Parisi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study
C. Leonardi et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
Atsuyuki Igarashi et al.
JOURNAL OF DERMATOLOGY (2012)
Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment
T. C. Lucka et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
Elizabeth A. Brezinski et al.
PLOS ONE (2012)
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events A Meta-analysis of Randomized Controlled Trials
Caitriona Ryan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
Tsen-Fang Tsai et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review
Phyllis I. Spuls et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Monoclonal antibodies and progressive multifocal leukoencephalopathy
Joseph R. Berger et al.
MABS (2009)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis
Gerald G. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Psoriasis assessment tools in clinical trials
SR Feldman et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and 'type 1' inflammatory gene expression
W Lew et al.
TRENDS IN IMMUNOLOGY (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
The immunologic basis for the treatment of psoriasis with new biologic agents
JG Krueger
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
Share Paper
